Medical Device Classification and Registration via ANVISA – clinical and regulatory affairs



Medical Device Classification and Registration via ANVISA – clinical and regulatory affairs

Published on 18/12/2025

Medical Device Classification and Registration via ANVISA – clinical and regulatory affairs

Brazil stands out as a critical market for medical devices. Understanding the classification and registration process with the National Health Surveillance Agency (ANVISA) is essential for companies looking to navigate the regulatory landscape effectively. This article provides a step-by-step tutorial guide on how to classify and register medical devices in Brazil, focusing on practical actions and documentation expectations.

Step 1: Understanding the Regulatory Framework in Brazil

Before engaging with ANVISA for medical device classification and registration, it is crucial to comprehend the regulatory framework. ANVISA is responsible for safeguarding public health in Brazil through the regulation of health products, which include medical devices.

Medical devices in Brazil are classified into four categories based on risk: Class I (low risk), Class II (medium risk), Class III (high risk), and Class IV (highest risk). The classification criteria are primarily outlined in the Resolutions (RDCs) released by ANVISA, most notably Resolution RDC No. 185/2001, which links to classifications reflected in the

ANVISA website.

To classify your medical device, review applicable RDCs and compare the intended use, technology, and patient risk associated with your product against existing classes. Engage experts in regulatory consulting pharma to ensure accurate classification. In some cases, engaging with ANVISA prior to formal registration can clarify the appropriate classification and alleviate future complications.

Step 2: Pre-Market Requirements and Dossier Preparation

Once classification is established, the next step involves preparing the necessary documentation for market entry. The documentation must prove that the device meets the regulatory standards set by ANVISA, focusing on manufacturing quality, safety, and efficacy.

The documentation usually includes:

  • Technical File: A comprehensive document outlining device specifications, intended use, manufacturing processes, and quality control measures.
  • Clinical Evaluation: A report detailing clinical data related to the safety and effectiveness of the device. This evaluation should align with the ICH-GCP guidelines.
  • Quality Management System (QMS) Certification: Evidence that the device’s manufacturing process follows Good Manufacturing Practices (GMP) as per ANVISA’s guidelines.
  • Instructions for Use (IFU): Comprehensive instructions detailing the device’s use, contraindications, risks, and maintenance.
  • Labeling: Affixed labels must conform to Brazilian regulations, providing necessary information for users.
  • Packaging Compliance: Assurance that packaging meets ANVISA’s standards for storage and transportation.
Also Read:  Pharmacovigilance Requirements: SAE Reporting and PSMF in Brazil – pharmaceutical regulatory intelligence

Preparing this dossier is a critical phase of the registration process. Companies should consider hiring regulatory consultants specialized in the local market to assist with documentation and ensure it meets ANVISA’s expectations. Engage internal resources for writing clinical notes to reinforce the clinical data part of your dossier.

Step 3: Submission of the Registration Dossier

After completing your documentation, the next step is the formal submission of the registration dossier. ANVISA allows submissions through its electronic system, the Sistema de Gestão de Produtos (SGP), which requires prior registration for an account.

The submission process consists of the following critical actions:

  • Complete the registration form: Fill out the specifics regarding the medical device and its intended application.
  • Upload documents: Attach all prepared documents in the required formats, ensuring that all information is clear and accurately represents the product.
  • Payment of fees: ANVISA mandates payment for registration processing, which varies depending on the device classification and operation scale.
  • Confirm submission: After submission, verify that online confirmation is received as proof of your submission date, which is essential for tracking the progress of the process.

Keep records of all communications sent and received from ANVISA. Effective communication is vital as these may be necessary if follow-up questions or clarifications arise during the review phase.

Step 4: ANVISA Review Process and Timeline

Upon receiving the registration dossier, ANVISA initiates a detailed review process, which may include technical and clinical assessments to confirm the safety and efficacy of the medical device. The duration of the review can substantially vary based on the device’s classification level, existing workloads at ANVISA, and the completeness of the submitted documentation.

Also Read:  Herbal Medicines and Natural Products Regulation – regulatory writer job

The review process typically includes:

  • Preliminary Verification: Initial checks to ensure all required documents are submitted and complete.
  • Technical Review: In-depth examination of the device information, including the technical file and clinical evaluation reports.
  • Quality Assessment: Evaluation of the QMS in place, focusing on compliance with GMP standards.
  • Communication of Findings: ANVISA may request additional information or clarifications, leading to further documentation submissions.

The standard timelines for the reviews vary, with Class I devices typically being processed faster than Class IV. It is essential to set expectations based on device classification and to maintain routine follow-ups with ANVISA to facilitate a timely review.

Step 5: Post-Market Surveillance and Compliance

Upon receiving the final approval and the registration number, companies must comply with ongoing regulatory requirements. Post-market surveillance is a critical action mandated by ANVISA to monitor the continued safety and efficacy of medical devices on the market.

Key components of post-market compliance include:

  • Real-time Monitoring: Establish mechanisms to collect and analyze data on the device’s performance in real-world settings.
  • Adverse Event Reporting: Maintain a system to report any adverse events related to the device to ANVISA in compliance with their reporting guidelines.
  • Periodic Reporting: Companies may be required to submit periodic safety updates or device performance summaries to ANVISA, outlining any safety issues encountered since the entry.
  • Recalls and Actions: Develop a strategy for addressing potential device recalls or required corrective actions as instructed by ANVISA.

Ongoing communication with regulatory authorities post-approval is vital to assure compliance. An effective pharmacovigilance system can foster a proactive approach to managing potential safety issues and maintaining regulatory compliance.

Also Read:  Regulatory Fees, Timelines, and Evaluation Stages – pharma regulations

Conclusion: Navigating the Regulatory Landscape in Brazil

Successfully navigating the medical device classification and registration process in Brazil with ANVISA requires a rigorous understanding of both regulatory frameworks and the submission process. Engaging in regulatory consulting pharma can provide companies with the necessary expertise throughout the process, improving their chances of successful market entry.

Adhering to each step discussed above will prepare involved stakeholders to meet the detailed requirements of ANVISA, ensuring both compliance and the device’s successful integration into the Brazilian market. It is imperative that medical device companies adopt a proactive stance and continuously stay informed of regulatory updates and modifications regarding medical device legislation.

Related Posts: